Report Subject - Market Access - Page 1

Learn More Charting Real World Data and Evidence - Activity and Capabilities (2018)

How do Real World Data (RWD) and Real World Evidence (RWE) professionals see their critical role developing? Which teams are using RWD/RWE, where is it providing most value and how might this change over the next 2...

Compare
Learn More The MSL Technology Survey (2018)

How is technology changing the face of MSL/KOL interaction and which technologies are set to take a greater role is this critical relationship? Which technologies are being employed to identify KOLs? What technology...

Compare
Learn More HTA in Europe: Key Success Factors for Positive HTA Recommendations

Is there a magic formula for achieving HTA approvals in Europe? Securing a HTA approval in Europe makes sound commercial sense but it's proving easier said than done. Negative or restrictive HTA recommendations are on...

Compare
Learn More Paying for Digital Health: Payer Insights

Payers love digital technologies that reduce health costs and deliver patient benefit–but who should pick up the tab? Digital technology is revolutionising healthcare from advanced electronic medical records and...

Compare
Learn More Biosimilars: US Payer Perspectives (2018)

US payers eye European biologics market with envy Biosimilars may be a roaring success in Europe but the picture in the US couldn't be more different. Once hailed as a solution to stem the tide of soaring drug spending,...

Compare
Learn More Benchmarking Pharma’s MSL Capabilities

Are you convinced your MSL teams are keeping up with evolving market practice? The best medical science liaison (MSL) teams have made significant changes to adapt to a whole new world. The pharma companies getting the...

Compare
Learn More Benchmarking Key Account Management Capabilities

Are your KAM teams firing on all cylinders? If, not, why not? What makes a great KAM (Key Account Manager) and KAM team and what are the personal attributes and operational environment that will deliver optimum...

Compare
Learn More KAM Metrics: Driving efficiency and measuring success

Sales numbers are no longer the gold standard for measuring commercial success. What is? The maturing key account management (KAM) model has transformed the way customer-facing teams operate: the challenge now is to use...

Compare
Learn More MSL Teams: Field Force size and structure

Medical Science Liaison (MSL) personnel play an ever crucial and widening role in communicating the value and science of increasingly complex therapies to opinion leaders and stakeholder groups. The challenge for senior...

Compare
Learn More Pricing and Reimbursement in Neurology

When first line treatments for neurological diseases such as Parkinson's Disease (PD) and Multiple Sclerosis (MS) have been around for years, it's understandable that when something new is approved, people want to try it...

Compare
Learn More Pricing and Reimbursement in Oncology: Payer views

As payer and stakeholder anger mounts, when will the oncology drug price bubble burst? Global cancer drug prices have increased by 10% every year between 1995 and 2013. That level of price inflation is not sustainable...

Compare
Learn More Ambitions in Health: Tech companies step up the pace

As investment $$$ pour into digital health projects, the scope and scale of tech giants' ambitions in health become ever clearer. From drug discovery and clinical research to patient monitoring and disease management,...

Compare
Learn More Value-Added Services in Oncology: What motivates payers?

Are your value-added services (VAS) in oncology meeting the needs of payers as well as patients and physicians? Payers are increasingly taking interest in beyond-the-pill services that improve patient adherence,...

Compare
Learn More Orphan Drug Launch Strategies: Case Studies

Achieving commercial success for orphan drugs requires specific strategies to be adopted, not least because market barriers are very different from those encountered when launching more common disease therapies. Lack of...

Compare
Learn More The Importance of Real World Evidence in Orphan Drugs

Proof of value is an imperative for orphan drug manufacturers: it's the only route to improving patient access and overcoming unmet therapeutic needs for rare conditions. Progress has been made with real world data (RWD)...

Compare
Learn More Market Access Team Structure and Function: Industry Survey 2017

This report gives a unique insight into how US and European market access teams are organized and how they are focusing their time on a day-to-day basis. Market Access Team Structure and Function: Industry Survey 2017...

Compare
Learn More Innovative drugs: Mapping the pricing, reimbursement and HTA landscape

Widespread patient access to innovative new products is being frustrated in non-US markets by Health Technology Assessments (HTA). Between January 2016 and June 2017, 58 innovative medicines were approved and launched in...

Compare
Learn More Value-Added Services in Cardiometabolic Diseases

Pharma's Value-Added Services (VAS) in cardiometabolic disease are not universally appreciated – why? Too often, useful programmes to monitor, educate and support patients are quietly dropped post launch. No wonder...

Compare
Learn More Riding the Wearables Trend: Opportunities for Pharma

Riding the Wearables Trend: Opportunities for Pharma Wearable health technology is causing a stir in Pharma with benefits across the business from smarter clinical research and improved patient monitoring and adherence...

Compare
Learn More The Future of Market Access in the US

The Future of Market Access in US When it comes to the affordability challenge, have payers and drugmakers reached a stalemate in the US? Pricing wars continue to rage, pharma initiatives are having lacklustre impact,...

Compare

Browse by

FirstWord Market Access Reports